Hydrogen sulfide-based anti-inflammatory and chemopreventive therapies: An experimental approach

Current Pharmaceutical Design

Volumn 21, Issue 21, 2015, Pages 3012-3022

  Flannigan, Kyle L ^a   Wallace, John L ^b,c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c Antibe Therapeutics Inc   (Canada)

Author keywords

Arthritis; Cancer; Colitis; Gastrointestinal; Inflammation; Ulcer

Indexed keywords

5' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADENOSINE PHOSPHATE; ANTIINFLAMMATORY AGENT; CYTOPROTECTIVE AGENT; HYDROGEN SULFIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TRACT; HUMAN; IN VIVO STUDY; INFLAMMATION; PRIORITY JOURNAL; ANIMAL; GASTROENTERITIS; GASTROINTESTINAL NEOPLASMS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; GASTROENTERITIS; GASTROINTESTINAL NEOPLASMS; HUMANS; HYDROGEN SULFIDE; PROTECTIVE AGENTS;

EID: 84931864585     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150514105413     Document Type: Article

References (141)

1. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996; 16: 1066-71.
2. Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphydration in liver and kidney of the rat. Biochem J 1982; 206: 267-77.
3. Morra MJ, Dick WA. Mechanisms of H2S production from cysteine and cystine by microorganisms isolated from soil by selective enrichment. Appl Environment Microbiol 1991; 57: 1413-7.
4. Shatalin K, Shatalina E, Mironov A, et al. H2S: a universal defense against antibiotics in bacteria. Science 2011; 334: 986-90.
5. Zanardo RC, Brancaleone V, Distrutti E, et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006; 20: 2118-20.
6. Kimura H. Hydrogen sulfide: its production, release and functions. Amino Acids 2011; 41: 113-21.
7. Wallace JL, Blackler RW, Chan MV, et al. Anti-Inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid Redox Signal 2014; (in press).
8. Wallace JL, Vong L, McKnight W, et al. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 2009; 137: 569-78.
9. Blackler RW, Gemici B, Manko A, et al. NSAIDgastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol 2014; 19C: 11-6.
10. Blackler RW, Motta JP, Manko A, et al. Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol 2014; in press. doi: 10.1111/bph.
11. Fiorucci S, Antonelli T, Distrutti E, et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by antiinflammatory non- steroidal drugs. Gastroenterology 2005; 129: 1210-24.
12. Fiorucci S, Distrutti E, Cirino G, et al. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006; 131: 259-71.
13. Wallace JL. Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. Antioxid Redox Signal 2010; 12: 1125-33.
14. Wallace JL, Ferraz JGP, Muscara MN. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal 2012; 17: 58-67.
15. Chattopadhyay M, Kodela R, Nath N, et al. Hydrogen sulfidereleasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol 2012; 83: 733-40.
16. Chattopadhyay M, Kodela R, Olson KR, et al. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun 2012; 419: 523-8.
17. Kashfi K. Anti-cancer activity of new designer hydrogen sulfidedonating hybrids. Antioxid Redox Signal 2013; 20: 831-46.
18. Lee Z, Zhou J, Chen CS, et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 2010; 6: e21077.
19. Elsheikh W, Blackler RW, Flannigan KL, et al. Enhanced chemopreventative effects of a hydrogen sulfide-releasing antiinflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide 2014; 41: 131-7.
20. Szabo C, Hellmich MR. Endogenously produced hydrogen sulfide supports tumor cell growth and proliferation. Cell Cycle 2013; 12: 2915-6.
21. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007; 6: 917-35.
22. Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci 2007; 28: 501-5.
23. Chan MV, Wallace JL. Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am J Physiol Gastrointest Liver Physiol 2013; 305: G467-73.
24. Wallace JL, Dicay M, McKnight W, et al. Hydrogen sulfide enhances ulcer healing in rats. FASEB J 2007; 21: 4070-6.
25. Martin GR, McKnight GW, Dicay MS, et al. Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Dig Dis Liver 2010; 42: 103-9.
26. Linden DR, Sha L, Mazzone A, et al. Production of the gaseous signal molecule hydrogen sulfide in mouse tissues. J Neurochem 2008; 106: 1577-85.
27. Shibuya N, Koike S, Tanaka M, et al. A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. Nat Commun 2013; 4: 1366.
28. Shibuya N, Tanaka M, Yoshida M, et al. 3- Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal 2009; 11: 703-14.
29. Shibuya N, Mikami Y, Kimura Y, et al. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. J Biochem 2009; 146: 623-26.
30. Flannigan KL, Ferraz JG, Wang R, et al. Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific pro-resolution mechanism. PLoS One 2013; 8: e71962.
31. Flannigan KL, Agbor TA, Blackler RW, et al. Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia- associated exacerbation of colitis. Proc Natl Acad Sci USA 2014; 111: 13559-64.
32. Flannigan KL, Agbor TA, Motta JP, et al. Pro-resolution effects of hydrogen sulfide during colitis are mediated through hypoxia inducible- factor-1α. FASEB J 2015; (in press).
33. Kamath AF, Chauhan AK, Kisucka J, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 2006; 107: 591-3.
34. Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322: 587-90.
35. Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 2000; 95: 2825-30.
36. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98: 112-7.
37. Vagianos K, Bernstein CN. Homocysteinemia and B vitamin status among adult patients with inflammatory bowel disease: a one-year prospective follow-up study. Inflamm Bowel Dis 2012; 18: 718-24.
38. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277-83.
39. Au-Yeung KK, Yip JC, Siow YL, et al. Folic acid inhibits homocysteine- induced superoxide anion production and nuclear factor kappa B activation in macrophages. Can J Physiol Pharmacol 2006; 84: 141-7.
40. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemostasis 2005; 3: 1646-54.
41. Davidson NJ, Leach MW, Fort MM, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10- deficient mice. J Exp Med 1996; 184: 241-51.
42. Kimura H. Metabolic turnover of hydrogen sulfide. Front Physiol 2012; 3: 101.
43. Stein A, Bailey SM. Redox biology of hydrogen sulfide: implications for physiology, pathophysiology, and pharmacology. Redox Biol 2013; 1: 32-9.
44. Lagoutte E, Mimoun S, Andriamihaja M, et al. Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes. Biochim Biophys Acta 2010; 1797: 1500-11.
45. Furne J, Springfield J, Koenig T, et al. Oxidation of hydrogen sulfide and methanethiol to thiosulfate by rat tissues: a specialized function of the colonic mucosa. Biochem Pharmacol 2001; 62: 255- 9.
46. Mimoun S, Andriamihaja M, Chaumontet C, et al. Detoxification of H2S by differentiated colonic epithelial cells: implication of the sulfide oxidizing unit and of the cell respiratory capacity. Antioxid Redox Signal 2012; 17: 1-10.
47. Wilson K, Mudra M, Furne J, et al. Differentiation of the roles of sulfide oxidase and rhodanese in the detoxification of sulfide by the colonic mucosa. Dig Dis Sci 2008; 53: 277-83.
48. Linden DR, Furne J, Stoltz GJ, et al. Sulphide quinone reductase contributes to hydrogen sulphide metabolism in murine peripheral tissues but not in the CNS. Br J Pharmacol 2011; 165: 2178-90.
49. Zhao W, Zhang J, Lu Y, et al. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 2001; 20: 6008-16.
50. Furne J, Saeed A, Levitt MD. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1479-85.
51. Shen X, Carlström M, Borniquel S, et al. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic Biol Med 2013; 60: 195-200.
52. Flannigan KL, McCoy KD, Wallace JL. Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol 2011; 301: G188-93.
53. Rey FE, Gonzalez MD, Cheng J et al. Metabolic niche of a prominent sulfate-reducing human gut bacterium. Proc Natl Acad Sci USA 2013; 110: 13582-7.
54. Babidge W, Millard S, Roediger W. Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis. Mol Cell Biochem 1998; 181: 117-24.
55. Roediger WE, Duncan A, Kapaniris O, et al. Sulphide impairment of substrate oxidation in rat colonocytes: a biochemical basis for ulcerative colitis? Clin Sci (Lond) 1993; 85: 623-27.
56. Attene-Ramos MS, Wagner ED, Plewa MJ, et al. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 2006; 4: 9- 14.
57. Levine J, Ellis CJ, Furne JK, et al. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 1998; 93: 83-7.
58. Picton R, Eggo MC, Merrill GA, et al. Mucosal protection against sulphide: importance of the enzyme rhodanese. Gut 2002; 50: 201- 5.
59. Guan Q, Wang X, Gao L, et al. Hydrogen sulfide suppresses high glucose-induced expression of intercellular adhesion molecule-1 in endothelial cells. J Cardiovasc Pharmacol 2013; 62: 278-84.
60. Kang K, Zhao M, Jiang H, et al. Role of hydrogen sulfide in hepatic ischemia-reperfusion injury in rats. Liver Transpl 2009; 15: 1306- 14.
61. Pan LL, Liu XH, Gong QH, et al. Hydrogen sulfide attenuated tumor necrosis factor-a-induced inflammatory signaling and dysfunction in vascular endothelial cells. PLoS One 2011; 6: e19766.
62. Brancaleone V, Mitidieri E, Flower RJ, et al. Annexin A1 mediates hydrogen sulfide properties in the control of inflammation. J Pharmacol Exp Ther 2014; 351: 96-104.
63. Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol 2005; 145: 275- 82.
64. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21: 325- 32.
65. Mariggio MA, Minunno V, Riccardi S, et al. Sulfide enhancement of PMN apoptosis. Immunopharmacol Immunotoxicol 1998; 20: 399-408.
66. Pálinkás Z, Furtmüller PG, Nagy A, et al. Interactions of hydrogen sulfide with myeloperoxidase. Br J Pharmacol 2014; in press
67. Whiteman M, Armstrong JS, Chu SH, et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite "scavenger"? J Neurochem 2004; 90: 765-8.
68. Whiteman M, Cheung NS, Zhu YZ, et al. Hydrogen sulfide: a novel mediator of hypochlorous acid mediated oxidative damage in the brain. Biochem Biophys Res Commun 2004; 326: 794-8.
69. Muzzaffar S, Shukla N, Bond M, et al. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. J Vasc Res 2008; 45: 521- 28.
70. Dufton N, Natividad J, Verdu EF, et al. Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. Sci Rep 2012; 2: 499.
71. Whiteman M, Li L, Rose P, et al. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal 2010; 12: 1147- 54.
72. Li L, Rossoni G, Sparatore A, et al. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 2007; 42: 706-19.
73. Fiorucci S, Orlandi S, Mencarelli A, et al. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol 2007; 150: 996-1002.
74. Sen N, Paul BD, Gadalla MM, et al. Hydrogen sulfide-linked sulfhydration of NF-κB mediates its antiapoptotic actions. Mol Cell 2012; 45: 13-24.
75. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014; 40: 315-27.
76. Ise F, Takasuka H, Hayashi S, et al. Stimulation of duodenal HCO3- secretion by hydrogen sulphide in rats: relation to prostaglandins, nitric oxide and sensory neurons. Acta Physiol 2011; 201: 117-26.
77. Motta JP, Flannigan KL, Agbor TA, et al. Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm Bowel Dis 2015; in press.
78. Carden DL, Granger DN. Pathophysiology of ischaemiareperfusion injury. J Pathol 2000; 190: 255-66.
79. Wallace JL, Caliendo G, Santagada V, et al. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007; 132: 261-71.
80. Bos EM, Leuvenink HG, Snijder PM, et al. Hydrogen sulfideinduced hypometabolism prevents renal ischemia/reperfusion injury. J Am Soc Nephrol 2009; 20: 1901-5.
81. Calvert JW, Coetzee WA, Lefer DJ. Novel insights into hydrogen sulfide--mediated cytoprotection. Antioxid Redox Signal 2010; 12: 1203-17.
82. Wallace JL, Caliendo G, Santagada V, et al. Markedly reduced toxicity of a hydrogen sulfide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010; 159: 1236-46.
83. Bos EM, Snijder PM, Jekel H, et al. Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury. Transpl Int 2012; 25: 897-908.
84. Guo C, Liang F, Shah Masood W, et al. Hydrogen sulfide protected gastric epithelial cell from ischemia/reperfusion injury by Keap1 ssulfhydration, MAPK dependent anti-apoptosis and NF-κB dependent anti-inflammation pathway. Eur J Pharmacol 2014; 725: 70-8.
85. Fu Z, Liu X, Geng B, et al. Hydrogen sulfide protects rat lung from ischemia-reperfusion injury. Life Sci 2008; 82: 1196-202.
86. Henderson PW, Weinstein AL, Sung J, et al. Hydrogen sulfide attenuates ischemia-reperfusion injury in in vitro and in vivo models of intestine free tissue transfer. Plast Reconstr Surg 2010; 125: 1670-8.
87. Liu Y, Kalogeris T, Wang M, et al. Hydrogen sulfide preconditioning or neutrophil depletion attenuates ischemia-reperfusion-induced mitochondrial dysfunction in rat small intestine. Am J Physiol Gastrointest Liver Physiol 2012; 302: G44-54.
88. Mard SA, Neisi N, Solgi G, et al. Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat. Dig Dis Sci 2012; 57: 1496-503.
89. Guo C, Liang F, Shah Masood W, et al. Hydrogen sulfide protected epithelial cell from ischemia/reperfusion injury by Keap 1 ssulfhydration, MAPK dependent anti-apoptosis and NF-kB dependent anti-inflammation pathway. Eur J Pharmacol 2014; 725: 70-8.
90. Mard SA, Askari H, Neisi N, et al. Antisecretory effect of hydrogen sulfide on gastric acid secretion and the involvement of nitric oxide. Biomed Res Int 2014; 2014: 480921.
91. Zayachkivska O, Havryluk O, Hrycevych N, Bula N, Grushka O, Wallace JL. Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. PLoS One 2014; 9: e11o688.2014
92. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88: 1547-65.
93. Wallace JL, Ma L. Inflammatory mediators in gastrointestinal defense and injury. Exp Biol Med (Maywood) 2001; 226: 1003-15.
94. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defence. FASEB J 2006; 10: 731-40.
95. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000; 119: 512-20.
96. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 2013; 19: 1861-76.
97. Blackler R, Syer S, Bolla M, et al. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One 2012; 7: e35196.
98. Goubern M, Andriamihaja M, Nübel T, et al. Sulfide, the first inorganic substrate for human cells. FASEB J 2007; 21: 1699-706.
99. Somasundaram S, Sigthorsson G, Simpson RJ, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAIDenteropathy in the rat. Aliment Pharmacol Ther 2000; 14: 639-50.
100. Mathai JC, Missner A, Kugler P, et al. No facilitator required for membrane transport of hydrogen sulfide. Proc Natl Acad Sci USA 2009; 106: 16633-8.
101. Li L, Rose P, Moore PK. Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol 2011; 51: 169 -87.
102. Oh GS, Pae HO, Lee BS, et al. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappa B via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med 2006; 41: 106-19
103. Lee IC, Kim SH Baek, et al. The involvement of Nrf2 in the protective effects of diallyl disulfide on carbon tetrachloride-induced hepatic oxidative damage and inflammatory response in rats. Food Chem Toxicol 2014; 63: 174-85.
104. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 2010; 7: 281-7.
105. Glover LE, Colgan SP. Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology 2011; 140: 1748-55.
106. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxiainducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114: 1098-106.
107. Cummins EP, Seeballuck F, Keely SJ, et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008; 134: 156-65.
108. Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008; 134: 145-55.
109. Kai S, Tanaka T, Daijo H, et al. Hydrogen sulfide inhibits hypoxiabut not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner. Antiox Redox Signal 2012; 16: 203-16.
110. Budde MW, Roth MB. Hydrogen sulfide increases hypoxiainducible factor-1 activity independently of von Hippel-Lindau tumor suppressor-1 in C. elegans. Mol Biol Cell 2010; 21: 212-7.
111. Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 1994; 91: 9926-30.
112. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38: 769-89.
113. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76- 86.
114. Kalayarasan S, Prabhu PN, Sriram N, et al. Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. Eur J Pharmacol 2009; 606: 162-71.
115. Calvert JW, Jha S, Gundewar S, et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 2009; 105: 365- 74.
116. Yang G, Zhao K, Ju Y, et al. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. Antioxid Redox Signal 2013; 18: 1906-19.
117. Hourihan JM, Kenna JG, Hayes JD. The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613. Antioxid Redox Signal 2013; 19: 465- 81.
118. Lee HJ, Mariappan MM, Feliers D, et al. Hydrogen sulfide inhibits high glucose-induced matrix protein synthesis by activating AMPactivated protein kinase in renal epithelial cells. J Biol Chem 2012; 287: 4451-61.
119. Wu YC, Wang XJ, Yu L, et al. Hydrogen sulfide lowers proliferation and induces protective autophagy in colon epithelial cells. PloS One 2012; 7: e37572.
120. Yang M, Huang Y, Chen J, et al. Activation of AMPK participates hydrogen sulfide-induced cyto-protective effect against dexamethasone in osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 2014; 454: 42-7.
121. Zhou X, Cao Y, Ao G, et al. CaMKKβ-dependent activation of AMP-activated protein kinase is critical to xuppressive effects of hydrogen sulfide on neuroinflammation. Antiox Redox Signal 2014; 21: 1741-58.
122. Ekundi-Valentim E, Santos KT, Camargo EA, et al. Differing effects of exogenous and endogenous hydrogen sulphide in carrageenan- induced knee joint synovitis in the rat. Br J Pharmacol 2010; 159: 1463-74
123. Ekundi-Valentim E, Mesquita FP, Santos KT, et al. A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide H2S-releasing derivative ATB- 346 in rats with carrageenan-induced synovitis. Med Gas Res 2013; 3: 24.
124. Wallace JL. Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig Dis Sci 2013; 58: 3088-93.
125. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase- 2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomized trials. BMJ 2006; 332: 1302-8.
126. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-22.
127. Fomenko I, Sklyarov A, Bondarchuk T, et al. Effects of conventional and hydrogen sulfide-releasing non-steroidal antiinflammatory drugs in rats with stress-induced and epinephrineinduced gastric damage. Stress 2014; 17: 528-37.
128. Gemici B, Elsheikh W, Feitosa KB, et al. H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide 2014; in press. doi: 10.1016/j.niox.2014.11.010
129. Wallace JL, Cirino G, Santagada V, et al. Hydrogen sulfide derivatives of nonsteroidal anti-inflammatory drugs. United States Patent Application No. WO/2008/009127.
130. Miles AM, Grisham MB. Antioxidant properties of 5- aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Adv Exp Med Biol 1995; 371B: 1317-21.
131. Distrutti E, Sediari L, Mencarelli A, et al. 5-Amino-2- hydroxybenzoic acid 4-(5-thioxo-5H-[1, 2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 2006; 319: 447-58.
132. Goodman JR, Grossman D. Aspirin and other NSAIDs as chemoprevention agents in melanoma, Cancer Prev Res 2014; 7: 557-64.
133. Yiannakopoulou E. Targeting epigenetic mechanisms and microRNAs by aspirin and other nonsteroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention, Cell Oncol 2014; 37: 167-78.
134. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-90.
135. Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: casecontrol study of subjects participating in the Nottingham faecal occult blood screening programme, BMJ1993; 307: 285-9.
136. Caliendo G, Cirino G, Santagada V, et al. Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem 2010; 53: 6275-86.
137. Sanokawa-Akakura R, Ostrakhovitch EA, Akakura S, et al. A H2SNampt dependent energetic circuit is critical to survival and cytoprotection from damage in cancer cells. PLoS One 2014; 9: e108537.
138. Yi L, Su Q. Molecular mechanisms for the anti-cancer effects of diallyl disulfide. Food Chem Toxicol 2013; 57: 362-70.
139. Szabo C, Coletta C, Chao C, et al. Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci USA 2013; 110: 12474-9.
140. Szabo C, Hellmich MR. Endogenously produced hydrogen sulfide supports tumor cell growth and proliferation. Cell Cycle 2013; 12: 2915-6.
141. Hellmich MR, Coletta C, Chao C, et al. The therapeutic potential of cystathionine-β-synthase/hydrogen sulfide inhibition in cancer. Antiox Redox Signal 2015; 22: 424-48.